ACIU240719P2500
- 0.05
- 0.000.00%
AC Immune Newsroom
BTIG Starts AC Immune With Buy Rating, $8 Price Target
AC Immune Analyst Ratings
Buy Rating Justified by Strategic Partnerships and Promising Pipeline in AC Immune SA
Buy Rating Affirmed: AC Immune's Promising Alzheimer's Vaccine and Strategic Takeda Partnership
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
AC Immune Analyst Ratings
Buy Rating for AC Immune SA on Promising Alzheimer's Vaccine Trial Design and Potential Accelerated Approval
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Buy Rating Affirmed for AC Immune SA Amid Promising Immunotherapy Program Developments
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), Wave Life Sciences (WVE) and AC Immune SA (ACIU)
AC Immune Analyst Ratings
Promising Outlook for AC Immune SA: Buy Rating Based on Potential Alzheimer Trials Success and Encouraging ABATE Study Progress
Analysts' Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)
Promising Outlook for AC Immune's Alzheimer's Disease Vaccine: A Comprehensive Analysis of Andrew Fein's Buy Rating
HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
AC Immune Analyst Ratings
AC Immune SA (ACIU) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
H.C. Wainwright Sticks to Its Buy Rating for AC Immune SA (ACIU)